The Magazine for Sleep Professionals
Monday, March 16, 2026
Nyxoah SA has announced an important investment in Belgium to further scale its manufacturing capacity to support its continued growth in the United States and international markets. In addition to its existing contract manufacturing operations in the United States, the Company will expand its manufacturing footprint in Wallonia, reflecting Nyxoah’s […]
Nyxoah SA announced that the U.S. Food and Drug Administration (FDA) has approved the Genio system (hypoglossal nerve stimulation) for a subset of patients with moderate to severe OSA with an Apnea-Hypopnea Index (AHI) of greater than or equal to 15 and less than or equal to 65. Genio is […]
Although there are more than half a billion individuals worldwide affected by moderate to severe obstructive sleep apnea (OSA), the vast majority still remain undiagnosed and many are untreated.1-2 Healthcare in the United States is facing shortages at every level—and these shortages are projected to increase sharply over the next […]
Inspire Medical Systems, Inc. announced that two leading physicians in sleep medicine and sleep surgery, Paul T. Hoff, M.D., M.S., an otolaryngologist, and Ruchir P. Patel, M.D., F.A.C.P., a sleep medicine specialist, will join Inspire as Vice President and senior Medical Director, effective April 21 and June 2, respectively. “Dr. […]
Nyxoah SA, which develops breakthrough treatment alternatives for obstructive sleep apnea (OSA) through neuromodulation, announced an update on the FDA approval process for the Genio system. On March 26, 2025, the Company announced that the U.S. Food and Drug Administration (FDA) issued an Approvable Letter regarding the Company’s Pre-Market Approval […]
Treating obstructive sleep apnea (OSA) is at an exciting crossroads where therapeutic advances are coming of age in the era of precision medicine. In the past, the only option was continuous positive airway pressure (CPAP) therapy. Now, there are many effective alternatives to manage sleep apnea and even more on […]
LivaNova PLC, a market-leading medical technology company, today announced that it met the primary endpoints for its OSPREY randomized controlled trial (RCT), Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation. Together with its safety endpoints, the RCT achieved statistical significance of its primary endpoint responder rates1,2 between the treatment […]
While continuous positive airway pressure (CPAP) is still the gold standard treatment for obstructive sleep apnea (OSA), it is well-established that many patients struggle with long-term adherence and tolerance.1 The literature indicates that CPAP non-compliance rates remain as high as 34% with little improvement over the last two decades.2 As […]
Inspire Medical Systems, Inc. announced today the publication of the reimbursement of Inspire therapy in France. “We are thrilled to offer our clinically proven treatment option for moderate to severe OSA to patients and physicians in France,” said Tim Herbert, Chairman and Chief Executive Officer of Inspire. “Inspire therapy is […]
Nyxoah SA today announced the appointment of Dr. Maurits S. Boon, MD as Chief Medical Officer. Dr. Boon joins Nyxoah from Thomas Jefferson University, where he will continue part-time as a professor and Vice Chairman, Education. He is dual board-certified in otolaryngology – head and neck surgery, as well as […]
